Literature DB >> 18556589

What animal models teach humans about tuberculosis.

Ashwin S Dharmadhikari1, Edward A Nardell.   

Abstract

Animal models have become standard tools for the study of a wide array of human infectious diseases. Although there are no true animal reservoirs for Mycobacterium tuberculosis, many different animal species are susceptible to infection with this organism and have served as valuable tools for the study of tuberculosis (TB). The most commonly used experimental animal models of TB are the mouse, rabbit, and guinea pig. Although substantial differences in TB susceptibility and disease manifestations exist between these species, they have contributed significantly to the understanding of TB immunopathogenesis, host genetic influence on infection, efficacy of antimicrobial therapy, and host/pathogen interactions that determine the outcome or severity of infection. Among the three species, mice are relatively resistant to TB infection, followed by rabbits and then guinea pigs, which are extremely vulnerable to infection. Mice are most often used in experiments on immune responses to TB infection and drug regimens against TB. Rabbits, unlike the other two animal models, develop cavitary TB and offer a means to study the factors leading to this form of the disease. Guinea pigs, due to their high susceptibility to infection, have been ideal for studies on airborne transmission and vaccine efficacy. In addition to these three species, TB research has occasionally involved nonhuman primates and cattle models. Current concepts in TB pathogenesis have also been derived from animal studies involving experimentally induced infections with related mycobacteria (e.g., Mycobacterium bovis) whose manifestations in select animal hosts mimic human TB.

Entities:  

Mesh:

Year:  2008        PMID: 18556589      PMCID: PMC4674828          DOI: 10.1165/rcmb.2008-0154TR

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  49 in total

Review 1.  Disease model: pulmonary tuberculosis.

Authors:  D N McMurray
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

2.  Pathogenicity of isoniazid-resistant tubercle bacilli and prophylaxis of tuberculosis in children.

Authors:  N RIST
Journal:  Am Rev Tuberc       Date:  1956-08

3.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  TLR9 activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response.

Authors:  Toshihiro Ito; Matthew Schaller; Cory M Hogaboam; Theodore J Standiford; Stephen W Chensue; Steven L Kunkel
Journal:  Eur J Immunol       Date:  2007-10       Impact factor: 5.532

Review 5.  The mouse as a useful model of tuberculosis.

Authors:  I M Orme
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

Review 6.  Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics.

Authors:  R G Hewinson; H M Vordermeier; B M Buddle
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

7.  Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Authors:  Anne J Lenaerts; Casey Bitting; Lisa Woolhiser; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

8.  Zoonotic tuberculosis (Mycobacterium bovis): memorandum from a WHO meeting (with the participation of FAO).

Authors: 
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

9.  On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis.

Authors:  M B LURIE; S ABRAMSON; A G HEPPLESTON
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

10.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  38 in total

1.  BCG vaccination in the cotton rat (Sigmodon hispidus) infected by the pulmonary route with virulent Mycobacterium tuberculosis.

Authors:  Christine T McFarland; Lan Ly; Amminikutty Jeevan; Toshiko Yamamoto; Bradley Weeks; Angelo Izzo; David McMurray
Journal:  Tuberculosis (Edinb)       Date:  2010-05-06       Impact factor: 3.131

Review 2.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.

Authors:  Shubhra Singh; Richa Dwivedi; Vinita Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

4.  Prokaryotic expression and in vitro functional analysis of IL-1β and MCP-1 from guinea pig.

Authors:  Vijaya R Dirisala; Amminikutty Jeevan; Lan H Ly; David N McMurray
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

5.  Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation.

Authors:  Elizabeth F Redente; David M Higgins; Lori D Dwyer-Nield; Ian M Orme; Mercedes Gonzalez-Juarrero; Alvin M Malkinson
Journal:  J Leukoc Biol       Date:  2010-04-01       Impact factor: 4.962

6.  Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis.

Authors:  Ajay Grover; Jolynn Troudt; Kimberly Arnett; Linda Izzo; Megan Lucas; Katie Strain; Christine McFarland; Yper Hall; David McMurray; Ann Williams; Karen Dobos; Angelo Izzo
Journal:  Tuberculosis (Edinb)       Date:  2011-10-01       Impact factor: 3.131

7.  Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.

Authors:  Catherine W M Ong; Paul T Elkington; Jon S Friedland
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

8.  Classification and reporting of severity experienced by animals used in scientific procedures: FELASA/ECLAM/ESLAV Working Group report.

Authors:  David Smith; David Anderson; Anne-Dominique Degryse; Carla Bol; Ana Criado; Alessia Ferrara; Nuno Henrique Franco; Istvan Gyertyan; Jose M Orellana; Grete Ostergaard; Orsolya Varga; Hanna-Marja Voipio
Journal:  Lab Anim       Date:  2018-02       Impact factor: 2.471

Review 9.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

10.  Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4.

Authors:  Jose Davila; Lixin Zhang; Carl F Marrs; Riza Durmaz; Zhenhua Yang
Journal:  J Biomed Biotechnol       Date:  2010-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.